Skip to content
Open access

PTHP-25 Integrative multi-scale characterization of oncogenesis and clonal dynamics in H3K27- and MAPK-altered diffuse midline gliomas

Nov 2026 · Neuro-Oncology · 0 citations

Abstract

Diffuse midline gliomas (DMG) are aggressive brain tumors occurring mainly in children that remain incurable. Although these tumors are driven by a common epigenetic dysregulation, most frequently through the H3K27M mutation, growing evidence highlights biological heterogeneity, resulting in variable survival outcomes and treatment responses. Recently, a subset of H3K27M DMGs harboring concomitant MAPK pathway alterations (BRAFV600E or FGFR1 mutations) has emerged as a distinct group with improved prognosis independently of established prognostic markers, including TP53 status. These tumors differ from classical DMGs by specific clinical, radiological, and pathological features and cluster within a distinct DNA methylation group. To further characterize this subgroup, we assembled an international cohort of 50 H3K27M/MAPK-altered DMG samples, including 13 paired samples collected before and after treatment. We performed integrative analyses combining bulk molecular profiling and single-nucleus RNA sequencing, together with longitudinal evaluation of clonal dynamics, treatment-associated evolution, and integration of clinical, radiological, and pathological data. Bulk molecular analyses confirmed a heterogeneous molecular profile and variable expression of MAPK alterations despite a largely conserved methylation signature. Clinically, patients showed prolonged survival and slower disease progression compared with classical H3K27M DMG. Calcifications were identified in a substantial proportion of tumors, whereas a nodular part was always present on MRI (and never only diffuse radiological presentation). Single-cell analyses revealed transcriptional programs overlapping with those observed in classical DMG, but with distinct proportions of cell states and fewer cycling cells. Longitudinal analyses demonstrated dynamic changes in the proportion of MAPK-mutated cells over time and after treatment, whereas the H3K27M-mutated population remained relatively stable, supporting the hypothesis of a H3K27M-only subclone. Paired samples additionally showed treatment-associated shifts in cellular state composition. These findings suggest that H3K27M/MAPK-altered DMGs exhibit previously underappreciated transcriptional and clonal heterogeneity, supporting the existence of distinct evolutionary trajectories and highlighting potential therapeutic vulnerabilities that warrant further investigation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.